The study is the first randomized trial to show that combining mRNA vaccine technology - which has been behind the development of successful COVID-19 vaccines - with a drug that revs up the immune response would offer a better result for patients with the most deadly type of skin cancer. Shionogi says Japan government to buy 1 million more COVID pill doses Shionogi & Co Ltd said on Tuesday the Japanese government agreed to purchase an additional 1 million doses of its oral treatment for COVID-19.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases